Despite a dip in overall revenue, Canopy Growth Corp (CGC) shows resilience with significant EBITDA improvements and strong ...

Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Canopy Growth (CGC) to C$4 from C$7 and keeps a Neutral rating ...

ON BAYSTREET The TSX Venture Exchange unloaded 0.78 points to 638.73. All but one of the 12 subgroups lost ground midday, weighed most by health-care, down 2.4%, communications, down 1.5%, and ...

Luc Mongeau, the newly appointed CEO, emphasized his commitment to advancing Canopy Growth toward sustained profitability and positive cash generation. He highlighted strengths in the medical cannabis ...

Canopy Growth Corporation ( NASDAQ: CGC) Q3 2025 Earnings Conference Call February 7, 2025 10:00 AM ET Aaron Grey - Alliance Global Partners Bill Kirk - ROTH Capital Partners Matt Bottomley - ...

Shares in Canopy Growth fell sharply Friday morning after the company's loss missed expectations in the fiscal third quarter. Shares fell over 18% to 3.27 Canadian dollars ($2.29).

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Canadian cannabis producer cuts debt load and shows revenue growth in key segments while pushing ahead with U.S. expansion.

Canopy Growth Corp. reported a loss of $121.9 million in its latest quarter compared with a loss of $216.8 million in the ...

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announces its financial results ...

Canopy Growth is continuing its run from yesterday, currently trading at $4.0400, up 0.3900, gaining 10.6849% on the TSX on ...